Indian drugmaker Biocon Ltd. is aiming to become the world’s top supplier of insulin in the coming years, its co-founder Kiran Mazumdar-Shaw said, by capturing growing demand for the critical drug while Big Pharma shifts its focus to other medicines.
“In five years, we could be the number one insulin company in the world,” the 73-year-old pharma billionaire and Biocon Executive Chairperson said in an interview with Bloomberg Television’s Latitude with Haslinda Amin. “We are one of the few companies globally that has the scale to address that opportunity.”
